MOCA, or Medicinal Organic Cannabis Australia, has introduced a new CBD isolate product for compounding pharmacies in Australia. This organic CBD isolate is an excellent option for pharmacies looking for a high-quality CBD product that is free from THC and other impurities.

CBD isolate is a purified form of CBD that is extracted from the cannabis plant. It is different from full-spectrum CBD products because it contains only CBD and no other compounds found in the plant. This makes it an excellent choice for people who want to use CBD without any THC or other psychoactive components.

MOCA's CBD isolate is an all-organic, GMP-certified product that is 99% pure. This means that it is of the highest quality and free from any impurities or contaminants. This purity makes it an ideal product for compounding pharmacies, as they can trust that they are using a safe and effective product in their formulations.

Compounding pharmacies in Australia can now order MOCA's CBD isolate for immediate delivery. This means that they can easily add CBD to their formulations and provide their customers with a high-quality product that meets their unique needs. The use of CBD in compounding is becoming increasingly popular, as more people are turning to CBD to manage a variety of health conditions.

One of the key benefits of using MOCA's CBD isolate is that it is free from THC. This means that patients can use the product without experiencing any psychoactive effects. It is also free from other impurities and contaminants, which ensures that it is safe and effective for use in compounding.

MOCA's CBD isolate is produced using organic farming practices, which ensures that the product is of the highest quality and free from harmful chemicals. This commitment to organic farming practices is part of MOCA's overall philosophy of sustainability and environmental responsibility.

The production process for MOCA's CBD isolate is rigorous and carefully controlled. This ensures that the product is of the highest quality and that it meets all relevant regulatory standards. The production process includes extraction, filtration, and purification steps to remove any impurities and ensure that the final product is 99% pure.

MOCA's CBD isolate is available in a range of quantities, making it easy for compounding pharmacies to order the amount they need for their formulations. The product is also available for immediate delivery, which means that pharmacies can receive the product quickly and efficiently.

In conclusion, MOCA's organic CBD isolate is an excellent product for compounding pharmacies in Australia. Its high quality and purity make it an ideal ingredient for use in formulations, and its THC-free status ensures that patients can use the product without experiencing any psychoactive effects. The product is available for immediate delivery in a range of quantities, making it easy for pharmacies to order the amount they need. MOCA's commitment to organic farming practices and sustainable production methods ensures that the product is of the highest quality and free from harmful chemicals. Overall, MOCA's CBD isolate is an excellent choice for compounding pharmacies looking for a safe, effective, and high-quality CBD product.

References 

1. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008 Sep;30(3):271-80. doi: 10.1590/s1516-44462008000300015. PMID: 18833429.

2. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. PMID: 26724101; PMCID: PMC4707667.

3. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389. PMID: 23108553; PMCID: PMC3481531.

4. Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. doi: 10.1007/s13311-015-0377-3. PMID: 26264914; PMCID: PMC4604171.

5. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Mar 2. PMID: 28232276.

6. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442. Epub 2007 Sep 10. PMID: 17828291; PMCID: PMC2219532.

These references highlight the potential therapeutic applications of CBD isolate in various conditions. However, it is essential to consult with a healthcare professional for personalized advice and guidance on the use of CBD isolate or any other cannabinoid for specific health concerns.